### Highlights of This Issue

#### SPECIAL FEATURES

##### CCR Translations

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5217</td>
<td>Overcoming Antiangiogenic Resistance</td>
<td>James C. Yao and Alexandria Phan</td>
</tr>
<tr>
<td></td>
<td>See article p. 5299</td>
<td></td>
</tr>
</tbody>
</table>

##### CCR Perspectives in Drug Approval

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

##### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5226</td>
<td>Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis</td>
<td>Michele De Palma and Luigi Naldini</td>
</tr>
<tr>
<td>5233</td>
<td>Prostate Cancer Immunotherapy</td>
<td>Kenneth F. May, Jr., James L. Gulley, Charles G. Drake, Glenn Dranoff, and Philip W. Kantoff</td>
</tr>
</tbody>
</table>

##### Special Report

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

##### Review

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

### HUMAN CANCER BIOLOGY

#### Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer


#### Clonal Relationship of Classical Hodgkin Lymphoma and its Recurrences

Ellen C. Obermann, Nadine Mueller, Alexander Rufle, Thomas Menter, Esther Mueller-Garamvoelgyi, Gieri Cathomas, Stephan Dirnhofer, and Alexandar Tzankov

#### FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo

Rachel Sharpe, Alex Pearson, Maria T. Herrera-Abreu, Damian Johnson, Alan Mackay, Jonathan C. Welti, Rachael Natrajian, Andrew R. Reynolds, Jorge S. Reis-Filho, Alan Ashworth, and Nicholas C. Turner

#### Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis

Sharanjot Saini, Shalana Majid, Soichiro Yamamura, Laura Tabatabai, Seong O. Suh, Varahram Shubhrayi, Yi Chen, Guoren Deng, Yuichiro Tanaka, and Rajvir Dahiya

### CANCER THERAPY: PRECLINICAL

#### Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

Elizabeth Allen, Ian B. Walters, and Douglas Hanahan

See commentary p. 5217
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
Dharminder Chauhan, Ze Tian, Bin Zhou, Deborah Kuhn, Robert Orłowski, Noopur Raje, Paul Richardson, and Kenneth C. Anderson

5322

Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake
Thorsten Fuereder, Thomas Wanek, Pamina Pflegerl, Agnes Jaeger-Lansky, Doris Hoellmayer, Sabine Strommer, Claudia Kuntner, Friedrich Wrba, Johannes Werzowa, Michael Hejna, Markus Müller, Oliver Langer, and Volker Wachek

5333

Regression of Glioma in Rat Models by Intranasal Application of Parvovirus H-1
Irina Kiprianova, Nadja Thomas, Ali Ayache, Manuel Fischer, Barbara Leuchs, Michèle Klein, Jean Rommelaere, and Jörg R. Schlehofer

5343

Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Christopher A. Klebanoff, Luca Gattinoni, Douglas C. Palmer, Pawel Muranski, Yun Ji, Christian S. Hinrichs, Zachary A. Borman, Siddhartha Roy, Christian S. Hinrichs, Zachary A. Borman, Siddhartha Roy, and Jörg R. Schlehofer

5353

PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase
Yi-He Ling, Miguel Aracil, Yiyu Zou, Ziqiang Yuan, Bo Lu, Josef Jimeno, Ana Maria Cuervo, and Roman Perez-Soler

5367

Targeting Src in Mucinous Ovarian Carcinoma
Koji Matsuo, Masato Nishimura, Justin N. Botsford-Miller, Jie Huang, Kakaban Komurov, Guillermo N. Armaiz-Pena, Mian M. K. Shahzad, Rebecca S. Stone, Ju Won Roh, Angela M. Sanguino, Chunhua Lu, Dwayne D. Im, Neil B. Rosenshien, Atsuko Sakakibara, Tadayoshi Nagano, Masato Yamashita, Takayuki Takeuchi, Fumiko Kiyonaga, Naoki Kaneko, and Masao Sasamata

IMAGING, DIAGNOSIS, PROGNOSIS

5443

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group

5379

Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy
Hifzar Rahman Siddique, Shrawan Kumar Mishra, R. Jeffery Karnes, and Mohammad Saleem

5392

Induction of HLA-DP4–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell
Makoto Tanaka, Marcus O. Butler, Sascha Ansén, Osamu Imatani, Alla Berezovskaya, Lee M. Nadler, and Naoto Hirano

5402

Resveratrol Selectively Induces DNA Damage, Independent of Smad4 Expression, in Its Efficacy against Human Head and Neck Squamous Cell Carcinoma
Alpna Tyagi, Mallikarjunna Gu, Takenori Takahata, Barbara Frederika, Chapla Agarwal, Sunitha Siritwinda, Rajesh Agarwal, and Robert A. Scalfani

5412

Role of Smac in Determining the Chemotherapeutic Response of Esophageal Squamous Cell Carcinoma
Yang Xu, Lanping Zhou, Jing Huang, Fang Liu, Jian Yu, Qimin Zhan, Lin Zhang, and Xiaohang Zhao

5423

Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressor, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models
Kentarou Yamanaka, Takahito Nakahara, Tomohiro Yamauchi, Aya Kita, Masahiro Takeuchi, Fumiko Kiyonaga, Naoki Kaneko, and Masao Sasamata

5432

Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90
Pramod P. Mehta, Pamela Whalen, Sangita M. Baxi, Pei-Pei Kung, Shinji Yamazaki, and Min-Jean Yin
BARD1 Expression Predicts Outcome in Colon Cancer
Judith C. Sporn, Torsten Hothorn, and Barbara Jung

Gene Expression Profiling of Fixed Tissues Identified Hypoxia-Inducible Factor-1α, VEGF, and Matrix Metalloproteinase-2 as Biomarkers of Lymph Node Metastasis in Hepatocellular Carcinoma
Zuo-Lin Xiang, Zhao-Chong Zeng, Jia Fan, Zhao-You Tang, Hai-Ying Zeng, and Dong-Mei Gao

CANCER THERAPY: CLINICAL
Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Stuart A. Grossman, Xiaobu Ye, Glenn Lesser, Andrew Sloan, Hetty Carraway, Serena Desideri, and Steven Plantadosi for the NABTT CNS Consortium

A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
Wan-Teck Lim, Quan-Sing Ng, Percy Ivy, Swan-Swan Leong, Onkar Singh, Balram Chowbay, Fei Gao, Choon Hua Thng, Boon-Cher Goh, Daniel Shao-Weng Tan, Tong San Koh, Chee-Keong Toh, and Eng-Huat Tan

CORRECTIONS
Correction: Regulation of HMGA1 Expression by MicroRNA-296 Affects Prostate Cancer Growth and Invasion

Correction: Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE
Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer
Cathinka Halle, Malin Lando, Debbie Hege Svendsrud, Trevor Clancy, Marit Holden, Kolbein Sundlor, Gunnar B. Kristensen, Ruth Holm, and Heidi Lyng

XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck
ABOUT THE COVER

Immunohistochemical analysis confirmed that YM155 reduced survivin protein levels, whereas docetaxel treatment increased p34 Thr-survivin protein at G2/M mitotic arrest. Furthermore, the concomitant treatment YM155 apparently decreased the docetaxel-induced survivin upregulation below the basal level in SK-MEL-5 human malignant melanoma cell. For further details, please see Yamanaka and colleagues on page 5423 in this issue.